Abstract: An isolated anti-CD47 antibody or fragment thereof has the ability of binding CD47 and competing with the binding of SIRPa to CD47, and comprises a heavy chain variable region comprising heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3; and a light chain variable region comprising light chain complementarity determining regions LCDR1, LCDR2, and LCDR3. A method for treating a disorder in which CD47 is overexpressed or upregulated in a subject, comprises using an isolated anti-CD47 antibody or fragment thereof having the ability of binding CD47 and competing with the binding of SIRPa to CD47. A bispecific antibody comprises a first antigen binding moiety that binds to human GPC3 (hGPC3); and a second antigen binding moiety that binds to human CD47 (hCD47).

Abstract: A soluble ACF and a truncated form thereof, a fusion protein thereof and preparation methods therefor. A soluble ACEI and a truncated form thereof, as well as a use of the fusion protein in the preparation of a drug for an ACEI-related disease.

Abstract: The present invention relates to anti-TIGIT antibodies and antigen-binding fragments thereof that bind to both human TIGIT and mouse TIGIT. The present application also provides are nucleotides encoding the antibodies or fragments thereof, compositions or combinations comprising the antibodies or fragments thereof, and uses of the antibodies or fragments thereof in treatment of immune-related disease such as cancers and viral infection.

Abstract: Provided are anti-AREG antibodies or immunoreactive fragments thereof for the treatment, diagnosis or prophylaxis of fibrotic diseases, including but not limited to renal fibrosis, hepatic fibrosis, pulmonary fibrosis, in particular, IPF. Polynucleotides or nucleic acid molecules encoding the antibodies, expression vectors, host cells and methods for making the antibodies are also provided. The anti-AREG antibodies specifically bind to AREG and block the function of AREG, through binding residues that locate in the EGF like domain.

Abstract: Provided are human antibodies that specifically bind to HBV Pre-S1 domain ligand and inhibit HBV or HDV infection, antibodies binding to a set of amino acid residues that are critical for viral receptor engagement, and uses of these antibodies to prevent, or treat or diagnose HBV or HDV infection.

Abstract: Provided are human antibodies that specifically bind to HBV Pre-S1 domain ligand and inhibit HBV or HDV infection, antibodies binding to a set of amino acid residues that are critical for viral receptor engagement, and uses of these antibodies to prevent, or treat or diagnose HBV or HDV infection.

Abstract: A method for treating HBV infection in a subject, comprising administering to the subject an anti-pre-S1 antibody or a fragment thereof at a dose of about 0.1 mg/kg to about 80 mg/kg. Also relates to an anti-pre-S1 antibody or a fragment thereof for use in treating HBV infection.

Abstract: Provided are anti-FGF19 antibodies that selectively target to N-terminus of fibroblast growth factor 19 (FGF19) and antigen-binding fragments thereof. Also provided are compositions and uses of said antibodies, as well as methods of treating a disease or disorder caused by or related to abnormal FGF19-FGFR4 signaling, e.g. cancer, by administering the anti-FGF19 antibodies.

Abstract: Disclosed are antibodies that bind to the stem region of influenza hemagglutinin in the neutral pH conformation, hemagglutinin epitopes in the stem region, and methods of making and using both.

Abstract: The present invention comprises human monoclonal antibodies that bind to PD-L1 (also known as programmed death ligand 1 or B7H1). Binding of the invented antibody to PD-L1 inhibits binding to its receptor, PD1 (programmed death 1), and ligand-mediated activities and can be used to treat cancer and chronic viral infections.

Abstract: Disclosed are markers for nasopharyngeal carcinoma (NPC) diagnosis and prognostic prediction, and use thereof. The INSL5 level in a plasma sample can be determined by means of ELISA. It was found that the INSL5 plasma level is significantly different between NPC patients and healthy population. The analysis results of a ROC curve show that an area under curve of INSL5 is 0.941, the critical value of the INSL5 level is 2.45 ng/ml, and the sensitivity and specificity thereof are 93.2% and 81.5% respectively. In the healthy cohort, the INSL5 level in EBV-positive plasma is significantly higher than that in EBV-negative plasma. The EBV-negative subjects comprise 34 healthy individuals and 72 NPC patients, and the INSL5 levels are observed to be significantly different between these two cohorts. The results of the ROC curve show that the area under curve of INSL5 is 0.988, the critical value of the INSL5 level is 2.25 ng/ml, and the sensitivity and specificity thereof are 97.2% and 91.2% respectively.

Abstract: Disclosed are antibodies that bind to the stem region of influenza hemagglutinin in the neutral pH conformation, hemagglutinin epitopes to the stem region, and methods of making and using both.

Abstract: Provided are human antibodies that specifically bind to HBV Pre-S1 domain ligand and inhibit HBV or HDV infection, antibodies binding to a set of amino acid residues that are critical for viral receptor engagement, and uses of these antibodies to prevent, or treat or diagnose HBV or HDV infection.

Abstract: The present invention comprises human monoclonal antibodies that bind to PD-L1 (also known as programmed death ligand 1 or B7H1). Binding of the invented antibody to PD-L1 inhibits binding to its receptor, PD1 (programmed death 1), and ligand-mediated activities and can be used to treat cancer and chronic viral infections.

Abstract: The present invention comprises a humanized monoclonal antibody that binds to the chemokine receptor CCR4. This antibody is derived from Mab 1567 and recognizes the same epitope. Binding of the invented antibody to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer. Moreover, the antibody is used in combination with vaccines to suppress the activity of regulatory T cells.

Abstract: Provided are human antibodies that specifically bind to HBV Pre-S1 domain ligand and inhibit HBV or HDV infection, antibodies binding to a set of amino acid residues that are critical for viral receptor engagement, and uses of these antibodies to prevent, or treat or diagnose HBV or HDV infection.

Abstract: The present invention provides affinity matured humanized monoclonal antibodies, bi-specific antibodies, antibody conjugates, and fusion proteins that bind to the chemokine receptor CCR4. This antibody is derived from mAb 1567 and recognizes the same epitope. Binding of the antibodies disclosed herein to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer. Moreover, the antibody is used in combination with vaccines to suppress the activity of regulatory T cells.

Abstract: Disclosed are antibodies that bind to the stem region of influenza hemagglutinin in the neutral pH conformation, hemagglutinin epitopes to the stem region, and methods of making and using both.

Abstract: The present invention comprises a humanized monoclonal antibody that binds to the human immunoglobulin heavy chain variable region germline gene VH1-69. This antibody is derived from Mab G6 and recognizes the same epitope. Moreover, the antibody is used in combination with vaccines to augment an immune response to the antigen.

Abstract: The present invention comprises human monoclonal antibodies that bind to PD-L1 (also known as programmed death ligand 1 or B7H1). Binding of the invented antibody to PD-L1 inhibits binding to its receptor, PD1 (programmed death 1), and ligand-mediated activities and can be used to treat cancer and chronic viral infections.